Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
- Conditions
- Recurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Mixed Phenotype Acute LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRefractory Acute Leukemia of Ambiguous LineageRefractory Acute Undifferentiated Leukemia
- Interventions
- Drug: CyclophosphamideDrug: CladribineDrug: CyclosporineDrug: CytarabineDrug: Mycophenolate SodiumBiological: FilgrastimProcedure: Hematopoietic Cell TransplantationDrug: MitoxantroneDrug: IdarubicinDrug: Mycophenolate MofetilDrug: FludarabineRadiation: Total-Body IrradiationProcedure: Multigated Acquisition ScanProcedure: EchocardiographyProcedure: X-Ray ImagingProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04375631
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
- Conditions
- Primary MyelofibrosisSecondary Myelofibrosis
- Interventions
- Drug: CyclophosphamideDrug: JAK InhibitorDrug: FludarabineBiological: Recombinant Granulocyte Colony-Stimulating FactorDrug: MelphalanDrug: Mycophenolate MofetilProcedure: Peripheral Blood Stem Cell TransplantationDrug: TacrolimusRadiation: Total-Body IrradiationProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen CollectionProcedure: EchocardiographyProcedure: Multigated Acquisition Scan
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04370301
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
- Conditions
- Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
- Interventions
- Biological: Cytokine induced memory-like NK cellsProcedure: LeukapheresisDrug: FludarabineDrug: Ara-CDrug: G-CSFDrug: Interleukin-2
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT04354025
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
- Conditions
- Acute LeukemiaMyelodysplastic SyndromeSecondary MyelofibrosisHematologic and Lymphocytic DisorderPrimary Myelofibrosis
- Interventions
- Drug: FludarabineDrug: Itacitinib AdipateDrug: MelphalanOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationDrug: SirolimusDrug: Tacrolimus
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 59
- Registration Number
- NCT04339101
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
- Conditions
- Autoimmune LymphoproliferativeCommon Variable ImmunodeficiencyImmune System DiseasesPrimary T-cell Immunodeficiency DisordersLymphoproliferative Disorders
- Interventions
- Drug: Busulfan test doseDrug: FludarabineDrug: BusulfanDrug: AlemtuzumabRadiation: Total body IrradiationProcedure: Allogeneic HSCTDrug: Tacrolimus (Tacro)Drug: Mycophenolate mofetil (MMF)Drug: Cyclophosphamide (Cytoxan)
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT04339777
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
- Conditions
- Non Hodgkin LymphomaAcute Lymphoblastic LeukemiaDiffuse Large B Cell LymphomaFollicular LymphomaPrimary Mediastinal Large B Cell LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- TCR2 Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT04323657
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
- Conditions
- HER2-positive Gastric CancerHER2-positive Metastatic Breast CancerLocally Advanced Solid TumorSolid TumorMetastatic Cancer
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Acepodia Biotech, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04319757
- Locations
- 🇺🇸
Northwestern Univeristy, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳Taipei Veteran General Hospital, Taipei, Taiwan
CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
- Conditions
- BPDCNB-ALLAML/MDST-ALL
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04318678
- Locations
- 🇺🇸
St Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 6
- Registration Number
- NCT04314843
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
🇺🇸Columbia University Medical Center, New York-Presbyterian Hospital, New York, New York, United States
Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for CD19-positive ALL
- Conditions
- CD19-positive ALL
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2020-03-11
- Lead Sponsor
- The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
- Target Recruit Count
- 20
- Registration Number
- NCT04303520
- Locations
- 🇨🇳
Henan Province of TCM, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.